March 31, 2022– Safety-net hospitals have been on the front lines of our national response to the COVID-19 public health emergency since it started in 2020. They have had to absorb massive changes in their day-to-day operations to serve waves of COVID patients. They scrambled to increase hospital bed and intensive care unit capacity, cared for COVID patients while taking … [Read more...]
Drugmakers Cutting 340B Discounts Reported Record Revenues Last Year
March 10, 2022– The 14 drug companies that have imposed or announced restrictions on safety-net hospital access to 340B drug pricing program discounts collectively brought in more than a half-trillion dollars in revenues in 2021. The banner year for the drugmakers occurred as hospitals reported increasing losses of 340B savings from the cuts. Last month, most drug companies … [Read more...]
A 340B Community Comes Together to Celebrate
By Maureen Testoni Feb. 17, 2022– In many ways, last month’s 340B Coalition Winter Conference in San Diego was a cause for celebration. We celebrated the first chance we had to come together in person as a community in two years. And we celebrated the start of a historic year for the 340B drug pricing program, which will turn 30 years old this November. When 340B … [Read more...]
GlaxoSmithKline Policy Threatens Asthma Care
Feb. 16, 2022– Just days after President Biden spoke out in support of the 340B drug pricing program, drug giant GlaxoSmithKline (GSK) announced it will begin withholding 340B discounts starting in April for most safety-net hospitals. That action will bring the number of drug companies violating the 340B law to 14. In 2021, GSK reported more than $45 billion in global sales, … [Read more...]
Survey Shows the Loss of 340B Savings is a Big and Growing Problem for Safety-Net Hospitals
Feb. 2, 2022– More than a dozen pharmaceutical companies have pulled back on 340B drug pricing program discounts that federal law requires them to offer safety-net hospitals that care for the nation’s patients who are in the most need. New survey data demonstrate how these drugmaker actions already have taken major bites out of the resources that hospitals rely on to fulfill … [Read more...]
Housing is Health: 340B Helps Address Social Determinants of Health for Patients Living with HIV
Jan. 18, 2022 – When Ellen Eaton, M.D., reflects on how important the 340B drug pricing program is to her patients living with HIV, one of the first people she thinks about is a woman she calls “Linda.” For many years, Linda struggled with substance use disorders. She lost custody of her children, was estranged from her family, had no income, and she was living without stable … [Read more...]
More Court Battles Ahead for 340B in 2022
Jan. 12, 2022– The dispute between safety-net hospitals and a growing group of drug companies over community-based pharmacies in the 340B drug pricing program is heading into a new phase of legal wrangling that ensures this fight will remain a dominant issue in the 340B world for months to come. As 2021 ended, two industry giants – Amgen and AbbVie – joined the group of … [Read more...]